Cargando…
Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain
Second-generation antipsychotics (SGAs) are the cornerstone of treatment for schizophrenia because of their high clinical efficacy. However, SGA treatment is associated with severe metabolic alterations and body weight gain, which can increase the risk of type 2 diabetes and cardiovascular disease,...
Autores principales: | Grajales, Diana, Ferreira, Vitor, Valverde, Ángela M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912706/ https://www.ncbi.nlm.nih.gov/pubmed/31671770 http://dx.doi.org/10.3390/cells8111336 |
Ejemplares similares
-
The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice
por: Grajales, Diana, et al.
Publicado: (2021) -
Schizophrenia Treatment with Second-Generation Antipsychotics: A Multi-Country Comparison of the Costs of Cardiovascular and Metabolic Adverse Events and Weight Gain
por: Kearns, Benjamin, et al.
Publicado: (2021) -
Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children
por: Bahr, S M, et al.
Publicado: (2015) -
S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020) -
Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
por: Teff, Karen L., et al.
Publicado: (2013)